Informations sur le produit
- DL-4-(3,4-Dichlorobenzoylamino)-5-(dipentylamino)-5-oxopentanoic Acid
- 4-[(3,4-Dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic Acid
- CR 1409
- (±)-4-[(3,4-Dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxo-pentanoic Acid
- 4-[(3,4-Dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxo-pentanoic Acid
- (+-)-4-(3,4-Dichlorobenzamido)-N,N-dipentylglutaramic acid
- 4-[(3,4-Dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid
- <span class="text-smallcaps">DL</span>-4-(3,4-Dichlorobenzoylamino)-5-(dipentylamino)-5-oxopentanoic acid
- Ccris 6857
- Cr 1409
- Voir d'autres synonymes
- D,L-4-(3,4-Dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pentanoic acid
- Lorglumida
- Lorglumida [Spanish]
- Lorglumide [INN]
- Lorglumidum
- Lorglumidum [Latin]
- N~2~-(3,4-dichlorobenzoyl)-N,N-dipentyl-alpha-glutamine
- Pentanoic acid, 4-((3,4-dichlorobenzoyl)amino)-5-(dipentylamino)-5-oxo-, (+-)-
- Sodium 4-{[4-Carboxylato-1-(Dipentylamino)-1-Oxobutan-2-Yl]Carbamoyl}-1,2-Dichlorobenzene
- Unii-Lad1Uq73Be
Applications Lorglumide is a specific cholecytokinin receptor antagonist. It is also an intermediate in synthesizing Lorglumide Sodium Salt (L469910), a nonpeptidic antagonist of the CCK A receptor, and minimally effective at the CCK B receptor. It blocks CCK -mediated muscle contraction, pancreatic growth and secretion.
References Makovec, F. et al.: J. Med. Chem., 35, 28 (1992)